Skip to content

Category: leber congenital amaurosis

ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial ProQR, a biotech company in the Netherlands, has treated its first patient in a Phase 1/2 clinical trial for QR-110, a therapy for people with Leber congenital amaurosis…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FDA Committee Unanimously Recommends Approval for Spark’s RPE65 Gene Therapy – Final Decision Due in January 2018 Ashley and Cole Carper traveled from Little Rock, AR, to tell their family’s story at the FDA hearing. Spark Therapeutics has…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies With five gene-therapy clinical trials underway or soon to begin, Applied Genetic Technologies Corporation (AGTC) is generating tremendous excitement for the potential to overcome vision loss from several inherited…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FFB-Funded Scientists Report on Nine Promising Translational Research Efforts

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FFB-Funded Scientists Report on Nine Promising Translational Research Efforts Translational research — moving promising science out of laboratories and into clinical trials — is essential to getting vision-saving, retinal-disease treatments out to the millions who need them. With…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy ProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest